Cargando…
MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer
The rapid onset of resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) limits its clinical utility in colorectal cancer (CRC) patients, and pan-erb-b2 receptor tyrosine kinase (ErbB) treatment strategy may be the alternative solution. The aim of this study was to deve...
Autores principales: | Zhang, Yuanzhou, Liang, Shunshun, Xiao, Bowen, Hu, Jingying, Pang, Yechun, Liu, Yuling, Yang, Juan, Ao, Junpin, Wei, Lin, Luo, Xiaoying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940899/ https://www.ncbi.nlm.nih.gov/pubmed/35319011 http://dx.doi.org/10.1038/s41419-022-04709-9 |
Ejemplares similares
-
MiR-103a promotes tumour growth and influences glucose metabolism in hepatocellular carcinoma
por: Liu, Yuling, et al.
Publicado: (2021) -
Folic acid restricts SARS-CoV-2 invasion by methylating ACE2
por: Zhang, Yuanzhou, et al.
Publicado: (2022) -
Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments
por: Wang, Debby D., et al.
Publicado: (2015) -
Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014) -
Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs
por: Lin, Tingting, et al.
Publicado: (2019)